Antiviral activity of CTC-8 against herpes simplex virus (HSV-1) in cell culture: Evidence for a selective antiviral effect via a cellular mechanism

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 4, 2003, Pages 217-223

  Fitzmaurice, Tim ^a   Harper, David R ^b   Field, Hugh J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Charterhouse Therapeutics Ltd   (United Kingdom)

Author keywords

Antiviral chemotherapy; CTC 8; Cyclopentenone; HSV; Prostaglandin

Indexed keywords

4 TERT BUTYLDIMETHYLSILYLOXY 2 CYCLOPENTEN 1 ONE; ACICLOVIR; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HERPES SIMPLEX VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

EID: 0142043354     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400406     Document Type: Article

References (16)

1. Coen DM (1996) Antiviral drug resistance in herpes simplex virus. Advances in Experimental Biology & Medicine, 394:49-57.
2. Darby G & Field HJ (1984) Latency and acquired resistance - problems in chemotherapy of herpesvirus infections. Pharmacology & Therapeutics 23:217-251.
3. Danishevsky SJ, Cabal MP & Chow K (1989) Novel stereospecific silyl group transfer reactions: practical routes to the prostaglandins. Journal of the American Chemical Society 111:3456-3457.
4. Evans TG, Berstein DI, Raborn GW, Harmenberg J, Kowalski J & Spruance SL (2002) Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydorcortisone cream (ME609) for treatment of UV radiation-induced herpes labialis. Antimicrobial Agents & Chemotherapy 46:1870-1874.
5. Field HJ, Bell SE, Elion GB, Nash AA & Wildy P (1979) Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrobial Agents & Chemotherapy 15: 554-561
6. Field H, McMillan A & Darby G (1981) The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs. Journal of Infectious Diseases 143:281-285.
7. Field HJ, Tewari D, Sutton D & Thackray AM (1995) Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrobial Agents & Chemotherapy 39:1114-1119.
8. Fleming DT, McQuillan GM, Johnson RE, Nahamias AJ, Aral SO, Lee FK and St Louis ME. Herpes simplex virus type 2 in the United States, 1976 to 1994. New England Journal of Medicine 1997 337:1105-1110.
9. Hill TJ, Field HJ & Blyth WA (1975) Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. Journal of General Virology 28: 341-353.
10. Kaufman HE (1981) Animal models in the development of antiviral therapy. In: Herpetic Eye Diseases, ed. HR Sundmacher. Bergman-Verlag, Munich, pp 231-236.
11. Newton AA (1982) Prostaglandins and the replication of herpes simplex type 1. In: Herpesviruses, Clinical, Pharmacological Basic Aspects. Ed. H Shiota, Y-C Cheng & WH Prusoff. Exerpta Medica, Amsterdam, pp 192-200.
12. Santoro MG. Antiviral activity of cyclopentenone prostanoids. Trends in Microbiology (1997) 5:276-281.
13. Santoro MG & Roberts SM (1999) Search for novel cytoprotective and antiviral prostanoids. Drugs News Perspective 12:395-400.
14. Schang LM (2002). Cellular proteins (cyclin-dependent kinases) as potential targets for antiviral drugs. Antiviral Chemistry & Chemotherapy 12:157-178.
15. Vyse AJ, Gay NJ, Siomka MJ, Gopal R, Gibbs T, Morgan-Capner P & Brown DW. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sexually Transmitted Infections 2000, 76:183-187.
16. Williams HP, Falcon MG & Jones BR (1977). Corticosteroids in the management of herpetic eye disease. Transactions of the Ophthalmological Society, UK97:341-344.